japanes
enceph
viru
jev
member
genu
flaviviru
famili
flavivirida
contain
singlestrand
positivesens
rna
genom
approxim
kb
length
encod
three
structur
protein
includ
capsid
c
membran
prm
envelop
e
seven
nonstructur
protein
jev
global
health
concern
sinc
first
discov
late
centuri
estim
clinic
case
associ
death
per
year
jev
infectionrel
clinic
symptom
includ
fever
headach
vomit
diarrhea
mental
statu
chang
sign
mening
irrit
ratio
surviv
psychiatr
sequela
perman
neurolog
approxim
although
morbid
mortal
decreas
use
variou
vaccin
sever
recent
research
identifi
number
compound
antijev
activ
nnonyldeoxynojirimycin
dehydroepiandrosteron
nmethylisatinbetathiosemicarbazon
deriv
sch
indirubin
manidipin
chlorpromazin
etanercept
minocyclin
therapi
beyond
intens
support
care
treat
patient
jev
avail
address
urgent
need
antijev
therapi
highcont
screen
hc
assay
perform
librari
natur
extract
contain
untap
reservoir
potent
novel
inhibitor
activ
biolog
pathway
discov
inhibitor
jev
infect
two
hit
fdaapprov
compound
ouabain
digoxin
identifi
inhibit
jev
infect
vitro
vivo
result
studi
expect
contribut
understand
biolog
jev
infect
provid
novel
host
target
develop
antijev
drug
hc
assayoptim
condit
contain
cell
densiti
infect
dose
assay
endpoint
assay
condit
hc
optim
follow
cell
densiti
cell
per
plate
multipl
infect
moi
endpoint
h
postinfect
signaltobas
sb
ratio
coeffici
variat
cv
z
factor
respect
demonstr
assay
robust
reproduct
largescal
screen
novel
antivir
compound
jev
infect
reveal
novel
target
inhibitor
jev
infect
immunofluoresc
assay
ifa
base
hc
assay
perform
screen
librari
natur
extract
antijev
activ
fig
tabl
shown
fig
c
compound
select
second
screen
solubl
dimethyl
sulfoxid
dmso
room
temperatur
absenc
obviou
cytotox
vero
cell
compound
exert
inhibit
jev
defin
prime
candid
base
criterion
compound
select
screen
reconfirm
result
carri
use
prime
candid
broader
concentr
rang
eight
hit
compound
select
base
concentrationdepend
inhibitori
effect
cell
viabil
fig
b
among
compound
ouabain
digoxin
subject
investig
high
select
index
si
defin
cytotox
concentr
inhibitori
concentr
similar
mechan
name
cardiac
glycosid
compound
act
inhibitor
nakatpas
respect
infect
vero
cell
digoxin
nm
ouabain
nm
display
inhibit
rate
abil
block
viru
reduc
decreas
concentr
fig
similarli
reproduct
could
greatli
inhibit
concentr
digoxin
ouabain
reach
nm
nm
respect
simultan
fluoresc
signal
increas
diminish
drug
concentr
fig
condit
infect
ouabain
digoxin
robustli
inhibit
viru
product
plaqu
assay
reduct
approxim
log
unit
highest
concentr
fig
e
sharp
decreas
jev
rna
level
also
detect
quantit
revers
transcript
pcr
qrtpcr
assay
particular
attenu
rna
level
strain
highdos
middledos
lowdosetr
group
indic
strong
inhibit
viral
replic
fig
f
inhibitori
effect
two
compound
infect
also
evalu
cell
cell
line
jevinfect
vero
cell
plaqu
assay
perform
detect
viral
titer
dosedepend
antijev
effect
similarli
observ
two
cell
line
fig
j
determin
cellular
process
drug
target
timeofaddit
experi
perform
fig
shown
fig
neither
digoxin
ouabain
show
suppress
jev
virucid
treatment
pretreat
howev
ouabain
show
robust
inhibit
jev
treatment
importantli
ad
posttreat
ouabain
digoxin
exert
full
inhibitori
effect
jev
infect
suggest
viral
replic
main
stage
drug
show
inhibitori
activ
confirm
hypothesi
cell
electropor
jev
replicon
treat
indic
concentr
ouabain
digoxin
reveal
appreci
reduct
luciferas
signal
h
postelectropor
fig
result
indic
drug
inhibit
jev
rna
synthesi
dosedepend
manner
neither
drug
inhibit
initi
translat
replicon
rna
confirm
drug
inhibit
jev
infect
replic
stage
nakatpas
target
cardiac
glycosid
found
date
confirm
whether
jev
inhibit
occur
via
blockad
nakatpas
infect
cell
treat
dmso
two
compound
presenc
increas
nacl
kcl
two
compound
inhibit
jev
doserespons
manner
furthermor
concentr
digoxin
jev
inhibit
reduc
decreas
nacl
fig
increas
kcl
fig
experiment
condit
result
ouabain
action
consist
digoxin
fig
indic
jevinhibit
effect
compound
posit
correl
extracellular
nacl
invers
correl
kcl
result
confirm
ouabain
digoxin
exert
antivir
effect
target
nakatpas
ouabain
exhibit
stronger
inhibitori
activ
jev
infect
examin
protect
effect
ouabain
jevinduc
lethal
use
balbc
mous
anticip
mice
jevinfect
vehicletr
group
start
show
symptom
includ
limb
paralysi
restrict
movement
piloerect
bodi
stiffen
wholebodi
tremor
day
postinfect
within
day
infect
mice
jevinfect
group
succumb
infect
ouabain
treatment
follow
jev
infect
increas
surviv
rate
nearli
anim
surviv
fig
mice
treat
ouabain
alon
show
littl
abnorm
behavior
result
suggest
ouabain
provid
effect
protect
jevinduc
mortal
relat
protect
effect
viral
load
histopatholog
chang
mous
brain
viral
titer
determin
mous
brain
section
collect
assay
day
postinfect
result
indic
progress
diseas
ouabain
treatment
significantli
reduc
viral
load
infect
mice
compar
untreat
infect
mice
notabl
plaqu
form
ouabaintr
group
day
postinfect
fig
similarli
appar
damag
brain
includ
mening
perivascular
cuf
vacuolar
degener
observ
jevinfect
vehicletr
group
day
postinfect
ouabain
treatment
remark
allevi
phenomena
fig
result
indic
allevi
histopatholog
chang
accompani
reduct
viral
load
well
reduct
mortal
rate
confirm
cur
effect
ouabain
viral
enceph
viral
load
brain
blood
spleen
also
evalu
earli
stage
infect
shown
fig
day
postinfect
viral
titer
brain
almost
undetect
ouabain
exhibit
littl
effect
viral
titer
brain
preclin
stage
accordingli
ouabain
littl
effect
decreas
viral
titer
blood
spleen
earlier
time
point
mostli
due
detect
viral
genom
copi
number
low
compar
notabl
titer
blood
decreas
sharpli
day
day
postinfect
line
characterist
viremia
caus
jev
result
indic
ouabain
could
allevi
histopatholog
chang
reduc
viral
load
brain
thu
protect
mice
jevinduc
lethal
confirm
cur
effect
ouabain
viral
enceph
jev
continu
spread
asia
part
world
caus
sever
clinic
manifest
perman
neurolog
psychiatr
sequela
current
safe
effect
treatment
jev
infect
recent
wang
et
al
perform
librari
screen
fdaapprov
compound
report
manidipin
calcium
blocker
use
treatment
hypertens
inhibit
jev
infect
vitro
vivo
similarli
fang
et
al
test
fdaapprov
drug
found
anxiolyt
drug
target
peripher
benzodiazepin
receptor
reduc
jev
infect
vitro
drug
screen
repurpos
becom
use
approach
identifi
antivir
drug
explor
novel
molecular
target
studi
viru
pathogenesi
address
urgent
need
antijev
therapi
present
librari
natur
extract
check
abil
inhibit
jev
infect
highcont
screen
assay
design
could
identifi
compound
inhibit
jev
viral
entri
translat
rna
synthesi
studi
eight
hit
compound
si
index
greater
found
exert
inhibitori
effect
jev
among
eight
compound
previous
report
possess
wide
spectrum
pharmacolog
effect
includ
antivir
activ
moreov
compound
lycorin
emodin
procyanidin
proven
effect
inhibit
flaviviru
hcv
infect
via
differ
mechan
result
demonstr
hc
assay
effect
credibl
top
two
compound
fdaapprov
nakatpas
inhibitor
ouabain
digoxin
cardiac
glycosid
similar
chemic
structur
use
treatment
cardiac
arrhythmia
hypotens
year
recent
ouabain
digoxin
proven
inhibit
differ
kind
virus
includ
envelop
virus
coronavirus
nonenvelop
virus
reovirus
dna
virus
human
cytomegaloviru
positivesens
rna
virus
chikungunya
viru
negativesens
rna
virus
lymphocyt
choriomening
viru
lcmv
notabl
tri
select
drugresist
variant
serial
passag
jev
use
increas
concentr
digoxin
ouabain
respect
howev
adapt
mutant
found
passag
either
drug
result
suggest
drug
might
exert
antivir
effect
target
cellular
protein
viral
protein
make
barrier
resist
difficult
overcom
cardiac
glycosid
act
via
inhibit
sodiumpotassium
ion
pump
lead
chang
intracellular
concentr
sodium
potassium
calcium
shown
play
essenti
role
mani
cellular
biosynthet
signal
vesicular
sort
pathway
studi
ouabain
exhibit
therapeut
effect
jev
infect
adult
mous
model
decreas
viral
load
allevi
patholog
injuri
brain
significantli
improv
surviv
rate
jevinfect
mice
propos
two
mechan
may
contribut
antivir
effect
first
ouabain
may
block
jev
infect
induc
cellular
stress
respons
ouabain
treatment
mammalian
cell
caus
interact
inositol
receptor
nakatpas
induc
calcium
oscil
activ
calciumdepend
transcript
factor
activ
protein
evid
suggest
cardiac
glycosid
mediat
inflammatori
process
via
activ
phosphoinositid
pathway
srcmitogenactiv
protein
kinas
pathway
signal
pathway
also
caus
activ
mani
gene
express
elicit
activ
includ
innat
immun
respons
growth
differenti
stimul
antivir
state
might
block
jev
infect
end
second
jev
could
replic
central
nervou
system
cn
infect
result
breakdown
bloodbrain
barrier
bbb
along
influx
inflammatori
cell
breakdown
bbb
caus
jev
infect
may
allow
bbbnonpermiss
ouabain
enter
brain
bind
murin
atpas
isoform
inhibit
viral
replic
neuron
togeth
find
provid
valuabl
inform
may
use
futur
clinic
trial
examin
effect
ouabain
jev
infect
moreov
result
indic
atpas
promis
pharmacolog
target
jev
infect
anim
experiment
procedur
carri
accord
ethic
guidelin
approv
anim
care
committe
wuhan
institut
virolog
permit
number
vero
cell
maintain
dulbecco
modifi
eagl
medium
dmem
hyclon
logan
ut
usa
supplement
fetal
bovin
serum
fb
gibco
grand
island
ny
usa
cell
maintain
minimum
essenti
medium
mem
hyclon
supplement
fb
jev
strain
gener
use
infecti
clone
kindli
provid
wakita
tokyo
metropolitan
institut
neurosci
genbank
access
previous
describ
respect
infecti
clone
plasmid
linear
subject
vitro
transcript
electropor
cell
three
day
later
supernat
collect
store
aliquot
viru
stock
propag
titrat
plaqu
assay
cell
cell
densiti
infect
dose
assay
endpoint
optim
hc
assay
differ
densiti
cell
per
well
vero
cell
infect
moi
valu
rang
cell
viabil
detect
differ
time
h
jev
inocul
appropri
cell
densiti
infect
dose
assay
endpoint
hc
assay
select
compar
signaltobas
ratio
sb
coeffici
variat
cv
z
valu
differ
condit
previous
describ
manidipin
dmso
use
posit
neg
control
respect
librari
compound
natur
extract
purchas
weikeqi
biotech
sichuan
china
compound
store
mm
stock
solut
dmso
use
shown
fig
vero
cell
dissoci
seed
densiti
cell
per
well
plate
overnight
incub
cell
monolay
treat
duplic
compound
final
concentr
h
infect
jev
strain
moi
h
infect
supernat
replac
fresh
medium
compound
ad
well
addit
h
incub
infect
stop
rins
well
phosphatebuff
salin
pb
fix
cell
paraformaldehyd
cell
permeabil
use
pb
triton
min
block
fb
gibco
follow
treatment
primari
antibodi
antijev
prm
fulllength
prm
express
escherichia
coli
cell
use
express
vector
purifi
protein
inject
rabbit
prepar
polyclon
antibodi
overnight
six
rins
pb
cell
stain
dylight
antibodi
rabbit
igg
kpl
gaithersburg
md
usa
nuclei
counterstain
dapi
sigmaaldrich
usa
nine
field
per
well
imag
operetta
highcont
imag
system
perkinelm
percentag
infect
dapiposit
cell
calcul
use
associ
harmoni
softwar
vero
plate
infect
jev
strain
moi
differ
concentr
h
ifa
assay
perform
describ
qrtpcr
plaqu
assay
carri
previous
report
timeofaddit
experi
perform
previous
describ
fig
vero
cell
infect
jev
strain
h
h
ouabain
digoxin
incub
cell
h
h
accord
follow
preinfect
h
infect
h
postinfect
h
exclud
possibl
direct
inactiv
effect
drug
virus
incub
drug
h
mixtur
dilut
infect
vero
cell
viru
titer
determin
plaqu
assay
h
later
ensur
effect
two
hit
drug
jev
replic
genbank
access
replicon
cdna
clone
structur
gene
replac
renilla
luciferas
rluc
gene
employ
quantit
evalu
inhibitori
effect
vitro
transcript
synthes
linear
jev
replicon
use
mmessag
mmachin
kit
albion
austin
tx
accord
manufactur
instruct
cell
electropor
vitro
transcript
gene
pulser
electropor
buffer
biorad
electropor
cuvett
electrod
gap
gene
pulser
ii
biorad
unit
set
v
puls
time
electropor
cell
plate
dmem
supplement
fb
compound
ad
medium
specifi
indic
time
postelectropor
cell
harvest
luciferas
activ
measur
use
rluc
assay
system
promega
madison
wi
vero
cell
seed
plate
treat
dmso
either
compound
dilut
medium
supplement
nacl
concentr
mm
kcl
concentr
mm
h
respect
jev
moi
ad
well
h
cell
supernat
remov
treat
indic
concentr
compound
ionsuppl
medium
addit
h
viru
titer
determin
plaqu
assay
use
cell
inhibit
rate
calcul
percentag
infect
cell
normal
dmsotreat
cell
least
triplic
repeat
experi
adult
male
balbc
mice
week
randomli
divid
three
group
jevinfect
vehicl
dmso
normal
salin
treat
group
jevinfect
ouabaintr
group
ouabaintr
group
infect
mice
infect
intraperiton
ip
dose
pfu
jev
infect
mice
ip
administ
ouabain
mgkg
bodi
weight
vehicl
control
everi
day
consecut
day
mice
sacrif
day
depend
experiment
design
blood
spleen
brain
sampl
collect
plaqu
assay
qrtpcr
histopatholog
investig
vectra
ss
perkinelm
viral
burden
determin
plaqu
assay
sampl
weigh
homogen
pb
homogen
clarifi
centrifug
g
min
dilut
serial
prior
infect
cell
viral
titer
adjust
sampl
volum
tissu
weight
calcul
titer
pfug
tissu
sampl
blood
jevinfect
mice
extract
rnaprep
pure
tissu
kit
tiangen
catalog
rnaprep
pure
blood
kit
tiangen
catalog
respect
jev
rna
level
determin
onestep
qrtpcr
abi
realtim
pcr
system
use
standard
cycl
condit
viral
burden
calcul
standard
curv
produc
use
serial
dilut
plasmid
carri
infecti
clone
histopatholog
investig
brain
tissu
collect
mice
fix
paraformaldehyd
hematoxylineosin
stain
protocol
follow
tissu
stain
student
test
log
rank
test
use
evalu
statist
signific
differ
valu
p
consid
statist
signific
